sellWeak cluster of 5
Robert Renninger sold $1,619 of LONA
VP of Finance at Athira Pharma, Inc.. 2,881 shares at an average of $0.56, traded Jan 2, 2025, filed Jan 3, 2025.
Warning score
15Value
$1,619
2,881 shares
Holdings after
89,724
-3% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +15RoleOfficer
- 0Trade size$2k at market
- 0Share of holdings soldSold 3.1% of holdings
- +15Cluster5 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0001415889-25-000527, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Nov 18, 2024 | AGrant or award Common Stock | +3,651 | $0.55 | $2,008 | 80,246 | Jan 3, 2025 |
| Dec 31, 2024 | MOption exercise Common Stock | +12,359 | $0.00 | $0 | 92,605 | Jan 3, 2025 |
| Jan 2, 2025 | SOpen-market sale Common Stock | -2,881 | $0.56 | $1,619 | 89,724 | Jan 3, 2025 |
| Dec 31, 2024 | MOption exercise Restricted Stock Unitsderivative | -12,359 | $0.00 | $0 | 24,718 | Jan 3, 2025 |
Related signals
Other insiders at Athira Pharma, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 15Weak | Athira Pharma, Inc. | Church Kevin CHIEF SCIENTIFIC OFFICER | $7,298 1,359 shares | -5% | |
| 30Weak | Athira Pharma, Inc. | Mark James Litton PRESIDENT and CEO | $28k 5,156 shares | -8% | |
| 15Weak | Athira Pharma, Inc. | Martin Javier San CHIEF MEDICAL OFFICER | $9,236 1,720 shares | -10% | |
| 15Weak | Athira Pharma, Inc. | Mark Worthington GENERAL COUNSEL and CCO | $7,131 1,328 shares | -7% | |
| 22Weak | Athira Pharma, Inc. | Robert Renninger CHIEF FINANCIAL OFFICER | $4,865 906 shares | -5% | |
| 25Weak | Athira Pharma, Inc. | Mark James Litton President and CEO | $18k 2,586 shares | -6% | |
| 20Weak | Athira Pharma, Inc. | Martin Javier San CHIEF MEDICAL OFFICER | $11k 1,644 shares | -14% | |
| 15Weak | Athira Pharma, Inc. | Church Kevin CHIEF SCIENTIFIC OFFICER | $6,027 876 shares | -4% | |
| 15Weak | Athira Pharma, Inc. | Mark Worthington General Counsel and CCO | $6,027 876 shares | -6% | |
| 22Weak | Athira Pharma, Inc. | Robert Renninger Chief Financial Officer | $2,043 297 shares | -2% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.